not a bad idea day trading this will probably be not that hard to do the next six months. Especially right before the third quarter earningsyou could probably dump it all and buy right back in the day they report earnings after it tanks 30 plus percent. .I will probably do that with my shares.
Capt. with due respect ...AMRN is not the only biotech stock out there . There are some considered with better near term fundamentals should you consider diversifying . Poster Laurent mentioned a real risk to AMRN's EU plans ...risk that Italy does not reimburse for Vazkepa. I have no way of evaluating the level of that risk other than to say it's not to be ignored. Other biotechs I follow ...ARDX ,strong growth in scripts ...major catalyst , hopefully by year end, would be passage of the Kidney Patient Act ...UNCY would also benefit from passage of that Act ...also FULC ...important data in Q4 .
After seeing what you did in your IRA, I sold all shares of AMRN in my IRA that had a basis of greater than $3, about 20-21k shares. I bought all but 3000 shares back at $0.66. I now have 90k AMRN shares with basis of $1.34 in my IRA.
In that sector rotation/consolidation market yesterday, our shares of CDMO and AVXL managed to gain. Most others like NVDA, NVDL lost.
Market Data 
Markets 
AI
